The use of heparin for the treatment of ulcerative colitis has been evaluated in several open and controlled trials, with varying outcomes.
Dr Ran and colleagues from China evaluated the efficacy and safety of heparin as supplemental therapy compared with conventional therapy in patients with ulcerative colitis.
All randomized trials comparing heparin supplementation to conventional therapy were included from electronic databases.
The research team performed statistical analysis with review manager 4.2.8.
Sub-analysis and sensitivity analysis were also performed.
The researchers found 8 randomized-controlled trials, investigating a total of 454 participants, met the inclusion criteria.
|The odds ratio for the efficacy of heparin use was 0.8|
|Alimentary Pharmacology & Therapeutics|
The odds ratio for the efficacy of heparin supplementation vs conventional therapy was 0.8.
The research team observed few serious adverse events.
The odds ratio for the efficacy of unfractionated heparin and low-molecular-weight heparin vs conventional therapy was 0.3, and 0.9, respectively.
The team noted that the odds ratio for the efficacy of heparin vs conventional therapy with placebo was 0.9.
Dr Ran's team concluded, "Our meta-analysis suggests that administration of heparin in patients with ulcerative colitis is safe, but no additive benefit over conventional therapy is indicated."